Monday, March 18, 2019

Discovery paves the way for new generation of anti-infective

Investigator(s): Michael R Yeaman, PhD

A discovery by researchers at the Los Angeles Biomedical Research Institute (LA BioMed) has uncovered a common blueprint for proteins that have antimicrobial properties. This finding opens the door to design and development of a new generation of anti-infectives active against pathogens that have become resistant to conventional antibiotics.

Monday, March 11, 2019

Product developed at LA BioMed is a safe, economical, available primary therapy

Investigator(s): Yutaka Niihara, MD, MPH

Last night’s episode of CBS’ “60 Minutes” brought much-needed awareness of the hardships faced by the estimated 25 million people around the world living with sickle cell disease. The broadcast highlighted an experimental gene therapy-based treatment that might someday even cure the disease. However, at this time, it is not available to the general public and remains in an experimental stage where potential complications and consistent efficacy are still being evaluated. Also, the procedure is potentially hugely expensive should it ever be commercialized.

Tuesday, February 12, 2019

 

LOS ANGELES - The Los Angeles Biomedical Research Institute (LA BioMed) and BioLabs, a network of shared lab facilities designed to manage all aspects of operations for high-potential, early-stage life science companies, today announced the Spring 2019 opening of a new Los Angeles bioscience innovation center.

Monday, February 11, 2019

Funds will go toward recruiting top researchers and improving facilities in the South Bay region of LA County – one of the nation’s top ten biotech clusters

Monday, December 10, 2018

New Program Creates a Triple Threat: Graduates with Clinical, Business & Research Skills

LA BioMed has launched a doctoral program in translational research, the first comprehensive degree of its kind. It will be co-located with LA BioMed’s research facilities and biotech incubator in Torrance, alongside a future bioscience tech park, level one trauma center, and academic teaching hospital.

Thursday, November 1, 2018
Missing file.

While male and female surgeons both work equally hard saving lives in the operating room, women in general surgery project earning significantly less than men. This disparity is due to women underestimating their future earning power, and to differing approaches to salary negotiation, according to an important new study from LA BioMed, an independent non-profit biomedical research organization.

Tuesday, October 23, 2018
Investigator(s): Loren G Miller, MD, MPH

Taking aim at one of the nation’s most common - but understudied - diseases, a team of local investigators have launched a groundbreaking study to determine the effectiveness of treatments for antibiotic-resistant skin infections.

The investigators from LA BioMed, one of the nation’s leading independent nonprofit research institutes, have been awarded a $5.3 million grant from the National Institutes of Health for their study, Short and Long Term Outcomes of Doxycycline Versus Trimethoprim-Sulfamethoxazole for Skin and Soft Tissue Infections Treatment.

Tuesday, October 16, 2018
Investigator(s): Ashraf S Ibrahim, PhD

Mucormycosis is a drug-resistant fungal infection that attacks patients with weakened immune systems and those who have suffered significant trauma. The infection can be easily missed by physicians because it is so rare and reliable diagnostic assay is lacking. Even when correctly diagnosed, it is often far too late and after the infection has spreads rapidly to vital organs, making most therapies ineffective. The mortality rate for those infected with mucormycosis is around 50%, according to the U.S. centers for Disease Control and Prevention.

Thursday, September 20, 2018

LA BioMed President and Chief Executive Officer David Meyer, Ph.D., is set to elaborate on the future of the local bioscience industry during a panel discussion later today at the Los Angeles County 2018 Bioscience Summit.  Meyer will also moderate a panel discussion about incubation and capital for start-ups.